{"id":"NCT03710889","sponsor":"Radius Health, Inc.","briefTitle":"Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption","officialTitle":"An Open-Label, Single-Arm, Multicenter Study to Evaluate the Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-09-20","primaryCompletion":"2020-07-15","completion":"2020-07-15","firstPosted":"2018-10-18","resultsPosted":"2021-10-15","lastUpdate":"2021-10-15"},"enrollment":23,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Osteoporosis, Postmenopausal","Osteoporosis","Osteoporosis Vertebral","Osteoporosis Risk","Osteoporosis Fracture","Osteoporosis Localized to Spine","Osteoporosis, Age-Related","Osteoporosis Senile","Osteoporosis of Vertebrae"],"interventions":[{"type":"DRUG","name":"Abaloparatide","otherNames":["TYMLOSÂ®","BA058"]}],"arms":[{"label":"Abaloparatide","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to measure the early effects of abaloparatide on tissue-based bone formation using samples obtained by transiliac crest bone biopsy after quadruple fluorochrome labeling.","primaryOutcome":{"measure":"Change From Baseline in Mineralizing Surface/Bone Surface (MS/BS) in the Cancellous Envelope at Month 3","timeFrame":"Baseline (Day 1), Month 3","effectByArm":[{"arm":"Abaloparatide","deltaMin":5.74,"sd":3.978}],"pValues":[{"comp":"OG000","p":"<0.0001"}]},"eligibility":{"minAge":"50 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":4,"countries":["United States"]},"refs":{"pmids":["26562265","28160873","33434314"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":23},"commonTop":["Nausea","Dizziness","Bursitis","Headache","Diarrhoea"]}}